Bo Hansen - Orphazyme Deputy Chairman of the Board
ORPHA Stock | DKK 1,094 89.40 8.90% |
Chairman
Dr. Bo Jesper Hansen, M.D., Ph.D. is Deputy Chairman of the Board of Directors of Orphazyme AS. He is Chairman of the Board of a public company Swedish Orphan Biovitrum and also Board Member of Gambro AB, MipSalus, TopoTarget AS, and Zymenex AS. He is founder of Scandinavian Medical Research through which he contracted as a medical advisor for Pfizer, Yamanouchi and Synthelab. He held various executive positions in Swedish Orphan International AB since 1993 and was its Chief Executive Position in the period from 1998 until 2010.
Age | 61 |
Professional Marks | Ph.D |
Phone | 45 39 17 82 72 |
Web | https://www.orphazyme.com |
Orphazyme Management Efficiency
The company has return on total asset (ROA) of (1.334) % which means that it has lost $1.334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.8658) %, meaning that it generated substantial loss on money invested by shareholders. Orphazyme's management efficiency ratios could be used to measure how well Orphazyme manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 10 records | CHAIRMAN Age | ||
Kurt Larsen | DSV Panalpina AS | 72 | |
Carol Sergeant | Danske Bank AS | 67 | |
Trond Westlie | Danske Bank AS | 54 | |
Ole Andersen | Danske Bank AS | 61 | |
Thomas Plenborg | DSV Panalpina AS | 53 | |
Vagn Soerensen | FLSmidth Co | 58 | |
Joergen Moeller | DSV Panalpina AS | 68 | |
Jan Nielsen | Danske Bank AS | 45 | |
Karsten Dybvad | Danske Bank AS | 63 | |
Torkil Bentzen | FLSmidth Co | 69 |
Management Performance
Return On Equity | -4.87 | |||
Return On Asset | -1.33 |
Orphazyme AS Leadership Team
Elected by the shareholders, the Orphazyme's board of directors comprises two types of representatives: Orphazyme inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orphazyme. The board's role is to monitor Orphazyme's management team and ensure that shareholders' interests are well served. Orphazyme's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orphazyme's outside directors are responsible for providing unbiased perspectives on the board's policies.
Remi Droller, Director | ||
Anders Hinsby, CEO | ||
Anders Hedegaard, Director | ||
MBA MSc, CFO CEO | ||
Georges Gemayel, Chairman of the Board | ||
Jennifer McCann, I US | ||
Bo Hansen, Deputy Chairman of the Board | ||
Anders Vadsholt, Interim Chief Executive Officer, Chief Financial Officer | ||
Thomas Blaettler, Chief Medical Officer | ||
Catherine Moukheibir, Director | ||
Sten Verland, Director | ||
Kim Stratton, Chief Executive Officer | ||
Martin Bonde, Director | ||
Thomas Jensen, Chief Scientific Officer | ||
Martijn Kleijwegt, Director |
Orphazyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orphazyme a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -4.87 | |||
Return On Asset | -1.33 | |||
Profit Margin | (2.76) % | |||
Operating Margin | (15.38) % | |||
Current Valuation | (12.81 M) | |||
Shares Outstanding | 35.31 M | |||
Shares Owned By Insiders | 1.36 % | |||
Shares Owned By Institutions | 8.13 % | |||
Price To Book | 0.47 X | |||
Price To Sales | 1.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orphazyme AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Orphazyme AS information on this page should be used as a complementary analysis to other Orphazyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Orphazyme Stock analysis
When running Orphazyme's price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |